Vasopeptidase inhibitors (Q34436579)

2 August 2017

1 reference

title

Vasopeptidase inhibitors. (English)

1 reference

2 August 2017

M A Weber

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

358

1 reference

2 August 2017

issue

9292

1 reference

2 August 2017

page(s)

1525-1532

1 reference

Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

The prevention of heart failure--a new agenda

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

1 reference

7 January 2021

Physiological role of silent receptors of atrial natriuretic factor

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Role of neutral endopeptidase in the metabolism of endothelin

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Effects of omapatrilat in low, normal, and high renin experimental hypertension

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Disposition and safety of omapatrilat in subjects with renal impairment

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Effects of omapatrilat on systemic arterial function in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(01)06584-9

7 January 2021

10.1016/S0140-6736(01)06584-9

Identifiers

DOI

1 reference

2 August 2017

1 reference